Healthcare / Drug Manufacturers - GeneralNYSE
$1082.89
-22.11 (-2.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $414.0M · quality 28.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$965.7B
P/E
38.4x
↑EV/EBITDA
31.8x
↑ROE
77.8%
↑Gross Margin
83.0%
↑Debt/Equity
1.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+7.2%
FCF CAGR
—
FCF margin
9.2%
FCF / Net income
0.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65.18B · net income $20.64B · FCF $5.96B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $65.18B | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B | $19.96B | $19.62B | $23.11B | $22.60B | $24.29B | $23.08B | $21.84B | $20.37B | $18.63B |
| Net Income | $20.64B | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | $-204.1M | $2.74B | $2.41B | $2.39B | $4.68B | $4.09B | $4.35B | $5.07B | $4.33B | $-2.07B | $2.95B |
| EBITDA | $31.69B | $31.69B | $18.81B | $11.85B | $8.66B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 22.95 | 22.95 | 11.71 | 5.80 | 6.57 | 6.12 | 6.79 | 8.89 | 3.13 | -0.19 | 2.58 | 2.26 | 2.23 | 4.32 | 3.66 | 3.90 | 4.58 | 3.94 | -1.89 | — |
| Gross Margin | 83.0% | 83.0% | 81.3% | 79.2% | 76.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 45.6% | 45.6% | 37.8% | 30.3% | 29.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | 31.7% | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% | 12.1% | 12.2% | 20.3% | 18.1% | 17.9% | 22.0% | 19.8% | -10.2% | 15.8% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 1.60 | 1.60 | 2.36 | 2.34 | 1.52 | 1.71 | 2.94 | 5.30 | 0.94 | 0.86 | 0.60 | 0.55 | 0.35 | 0.24 | 0.37 | 0.40 | 0.55 | — | — | — |
| Current Ratio | 1.50 | 1.50 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $5.96B | $5.96B | $414.0M | $-3.15B | $4.60B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||||
| ROE | 77.8% | 77.8% | 74.2% | 48.6% | 58.6% | 62.2% | 109.8% | 319.1% | 32.9% | -1.8% | 19.5% | 16.5% | 15.5% | 26.6% | 27.7% | 32.1% | 40.8% | — | — | — |
| Valuation | ||||||||||||||||||||
| P/E | 38.43 | 38.43 | 66.78 | 106.65 | 55.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 31.84 | 31.84 | 39.21 | 49.03 | 41.46 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 36.70 | 36.70 | 49.53 | 51.87 | 32.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 44.7% | 44.7% | 32.0% | 19.6% | — | 15.4% | 9.9% | 3.8% | 7.6% | -5.9% | 6.3% | 1.7% | -15.1% | 2.3% | -6.9% | 5.2% | 5.7% | 7.2% | 9.3% | — |
| EPS Growth | 96.0% | 96.0% | 101.9% | -11.7% | — | -9.9% | -23.6% | 184.0% | 1747.4% | -107.4% | 14.2% | 1.3% | -48.4% | 18.0% | -6.2% | -14.8% | 16.2% | 308.5% | — | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
61.2%
EPS terminal req.
$96.09
Spread vs growth
34.8%
5Y implied EPS CAGR
38.3%
EPS terminal req.
$116.27
Spread vs growth
57.7%
10Y implied EPS CAGR
23.4%
EPS terminal req.
$187.25
Spread vs growth
72.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+47.4%
Start / end P/E
63.0x → 47.2x
EPS bridge
11.71 → 22.95
Residual
-24.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.